|
What were your educational needs at the start of the activity? | |
Were your educational needs met? | |
Describe the prevalence and associated risk of familial hypercholesterolemia (FH) in order to increase awareness and understanding of the disease | |
Describe the importance of universal screening during childhood and cascade lipid screening of family members of known FH patients | |
Review management strategies to improve the care of patients with FH and reduce their elevated risk | |
Evaluate the clinical effects, safety and efficacy data for current and new treatment options for FH patients | |
Appraise treatment recommendations and evidence for screening, diagnosing and treating FH in both pediatric and adult patients (including women of childbearing potential and during pregnancy) | |
If "Not Met", please explain for each objective.
|
Anne C. Goldberg, MD | |
Jennifer G. Robinson, MD, MPH | |
Samuel S. Gidding, MD, PhD | |
Peter P. Toth, MD | |
Matthew K. Ito, PharmD | |
Did the speakers encourage questions/discussion or other participation from the audience?
| |
If the answer is no, please explain: | |
Was the content presented examined with sceintific rigor and evidence-based? | |
Was the scope, depth, and level of content appropriate? | |
Did the invitation and syllabus accurately convey the purpose and content? | |
Did the speaker provide a disclosure and disclose any off-label/investigational use of products discussed during their presentation? | |
Were the activities (e.g. speaker questions/discussion, case studies) that assessed learning appropriate? | |
Was the acitivity fair, balanced, and free of commercial bias? | |
If you answered 1, 2, or 3 in the above question, please describe the factors that contributed to the bias:
|
As a result of participating in this activity, what will you do differently to improve the care of your patients? (Note: You will be reminded of this answer in a follow-up email survey)
|
Implementation of Treatment Guidelines | |
Clinical Trial Updates | |
Genetic disorders and testing | |
Advanced lipid testing | |
Emerging biomarkers of atherosclerosis | |
Atherosclerosis Imaging | |
Hypertriglyceridemia | |
Metabolic syndrome, diabetes, insulin resistance | |
Hypertension | |
Obesity management and weight loss | |
Acute Coranary Syndrome | |
HDL-C therapies | |
Aggresive LDL-C lowering through combination therapies | |
Special Populations: Women, Pediatrics, Ethnic Groups, HIV | |
Other: | |
Additional comments or suggestions for improvement? | |
|